Biotargeted nanomedicines for cancer: six tenets before you begin

Area of Science:

• Nanomedicine
• Oncology
• Drug Delivery

Background:

• The concept of a 'magic bullet' for targeted therapy, first proposed by Paul Ehrlich, continues to inspire.
• Developing effective biotargeted nanomedicines requires interdisciplinary collaboration.

Purpose of the Study:

• To address conceptual and practical challenges in developing biotargeted nanomedicines for cancer.
• To highlight key principles for translating nanomedicine research into clinical practice.

Main Methods:

• Formation of the Biotargeting Working Group, comprising over 50 experts from diverse fields.
• Consensus-building and knowledge synthesis from leaders in biology, chemistry, engineering, medicine, and regulatory affairs.

Main Results:

• Identification of six core tenets for the development of biotargeted cancer nanomedicines.
• Emphasis on the necessity of integrating expertise across multiple scientific and clinical disciplines.

Conclusions:

• A multidisciplinary approach is crucial for advancing biotargeted nanomedicines from basic science to clinical application.
• The identified tenets provide a framework for overcoming translational barriers in nanomedicine development for cancer.